venture
Atlas Venture Raises $400M Opportunity Fund to Bolster Biotech Portfolio
Atlas Venture; $400M growth fund; biotech startups; Opportunity Fund III; portfolio support; venture capital; late-stage funding; biopharma investment
Funding Drought Puts Pressure on Cell Therapy Startups Like Appia Bio
Appia Bio; cell therapy; funding drought; biotech; venture capital; Series A financing; ACUA platform; CAR-iNKT cells
Shankar Ramaswamy’s Kriya Therapeutics Raises $313M for Gene Therapy Advancements
Kriya Therapeutics; Shankar Ramaswamy; gene therapy; biotech funding; fundraising; biotechnology; venture capital; 2025
Dispatch Bio Launches with $216M and CAR-T Pioneer Carl June to Advance Universal Solid Tumor Immunotherapy
Dispatch Bio; solid tumors; immunotherapy; CAR-T; Carl June; Series A funding; Flare platform; Parker Institute for Cancer Immunotherapy; ARCH Venture Partners; universal cancer treatment
Novartis Gains World-First Approval of Malaria Treatment for Babies
Novartis; malaria; Coartem Baby; Swissmedic; newborns; infants; Africa; approval; artemether-lumefantrine; Medicines for Malaria Venture; not-for-profit
Sofinnova Partners Launches Three New Biotechs with €165M Acceleration Fund
Sofinnova Partners, biotech acceleration fund, BioClec, Forth Therapeutics, Signadori Bio, venture capital, pharmaceutical backing
Sofinnova Partners Secures €1.2 Billion for Life Sciences Innovation
Venture capital, biotech, medtech, digital medicine, industrial biotech, healthcare, sustainability
New year starts with a bang as trio of venture financings brings in $382M
Venture capital, Biotech funding, Megarounds, Tenvie Therapeutics, Private financing, Life sciences investments
Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases
Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners
Tenvie Therapeutics Launches with $200 Million to Revolutionize Neurological Disease Treatment
Tenvie Therapeutics, neurological diseases, small molecule therapies, Denali Therapeutics, ARCH Venture Partners, F-Prime Capital, Mubadala Capital